共 50 条
- [11] Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years UpdateBLOOD, 2024, 144 : 1441 - 1442Senapati, JayastuJabbour, EliasJain, NitinHaddad, Fadi G.Garcia-Manero, GuillermoDaver, NavalKadia, Tapan M.Ravandi, FarhadSasaki, KojiDinardo, Courtney D.Takahashi, KoichiGarris, RebeccaJacob, JovittaValero, Yesid AlvaradoMontalban-Bravo, GuillermoShort, Nicholas J.Kantarjian, Hagop
- [12] Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemiaJOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)Kantarjian, HagopHaddad, Fadi G.Jain, NitinSasaki, KojiShort, Nicholas J.Loghavi, SanamKanagal-Shamanna, RashmiJorgensen, JeffreyKhouri, IssaKebriaei, PartowAlvarado, YesidKadia, TapanPaul, ShilpaGarcia-Manero, GuillermoDabaja, BouthainaYilmaz, MusaJacob, JovittaGarris, RebeccaO'Brien, SusanRavandi, FarhadJabbour, Elias
- [13] Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemiaJournal of Hematology & Oncology, 16Hagop KantarjianFadi G. HaddadNitin JainKoji SasakiNicholas J. ShortSanam LoghaviRashmi Kanagal-ShamannaJeffrey JorgensenIssa KhouriPartow KebriaeiYesid AlvaradoTapan KadiaShilpa PaulGuillermo Garcia-ManeroBouthaina DabajaMusa YilmazJovitta JacobRebecca GarrisSusan O’BrienFarhad RavandiElias Jabbour
- [14] A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic LeukemiaBLOOD, 2017, 130Short, Nicholas J.Kantarjian, Hagop M.Ravandi, FarhadHuang, XuelinJain, NitinDaver, NavalThomas, Deborah A.Pemmaraju, NaveenKhouri, RitaKhoury, Joseph DavidJorgensen, Jeffrey L.Alvarado, YesidSasaki, KojiKonopleva, MarinaGarcia-Manero, GuillermoKadia, TapanCortes, Jorge E.Benton, Christopher B.Borthakur, GautamBurger, Jan A.Ohanian, MaroWierda, William G.Estrov, ZeevKornblau, StevenDiNardo, Courtney D.Ferrajoli, AlessandraJacob, JovittaManzoor, AmeenaGarris, RebeccaO'Brien, Susan M.Jabbour, Elias J.
- [15] Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD, With or Without Blinatumomab, Is Highly Effective in Patients With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First SalvageCANCER, 2018, 124 (20) : 4044 - 4055Jabbour, EliasSasaki, KojiRavandi, FarhadHuang, XuelinShort, Nicholas J.Khouri, MariaKebriaei, PartowBurger, JanKhoury, JosephJorgensen, JeffreyJain, NitinKonopleva, MarinaGarcia-Manero, GuillermoKadia, TapanCortes, JorgeJacob, JovittaMontalbano, KathrynGarris, RebeccaO'Brien, SusanKantarjian, Hagop M.
- [16] Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)BLOOD, 2017, 130Assi, RitaKantarjian, Hagop M.Khouri, RitaRavandi, FarhadKebriaei, PartowShort, Nicholas J.Thomas, Deborah A.Garcia-Manero, GuillermoChamplin, Richard E.Kadia, TapanCortes, Jorge E.Jain, NitinKonopleva, MarinaEstrov, ZeevTakahashi, KoichiSasaki, KojiJacob, JovittaManzoor, AmeenaGarris, RebeccaO'Brien, Susan M.Jabbour, Elias J.
- [17] Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic LeukemiaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (04): : e168 - e173Short, Nicholas J.Jabbour, EliasJamison, TrevorPaul, ShilpaCuglievan, BrankoMcCall, DavidGibson, AmberJain, NitinHaddad, Fadi G.Nasr, Lewis F.Marx, Kayleigh R.Rausch, CaitlinSavoy, J. MichaelGarris, RebeccaRavandi, FarhadKantarjian, Hagop
- [18] Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trialLANCET HAEMATOLOGY, 2023, 10 (06): : E433 - E444Jabbour, EliasShort, Nicholas J.Senapati, JayastuJain, NitinHuang, XuelinDaver, NavalDiNardo, CourtneyPemmaraju, NaveenWierda, WilliamGarcia-Manero, GuillermoBravo, Guillermo MontalbanSasaki, KojiKadia, Tapan M.Khoury, JosephWang, Sa A.Haddad, Fadi G.Jacob, JovittaGarris, RebeccaRavandi, FarhadKantarjian, Hagop M.
- [19] Low-intensity chemotherapy (mini-HCVD) and ponatinib followed by blinatumomab (blina) and ponatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL): A phase II studyJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Nasr, Lewis FadyJabbour, EliasHaddad, FadiShort, Nicholas JamesMacaron, WalidNasnas, Cedric ChristopheZoghbi, MarianneIssa, Ghayas C.Yilmaz, MusaDaver, Naval GuastadPemmaraju, NaveenMasarova, LuciaRavandi, FarhadJain, NitinDeen, WuliamatuLoiselle, ChristopherWaller, LourdesBanks, GlendaGarris, RebeccaKantarjian, Hagop M.
- [20] Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic LeukemiaBLOOD, 2024, 144 : 1439 - 1441Nguyen, DanielKantarjian, HagopShort, Nicholas J.Jain, NitinHaddad, Fadi G.Yilmaz, MusaFerrajoli, AlessandraKadia, Tapan M.Valero, Yesid AlvaradoMaiti, AbhishekZoghbi, MarianneSenapati, JayastuGarris, RebeccaZhao, MinKonopleva, MarinaRavandi, FarhadJabbour, Elias